These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 38030572)

  • 21. COVID-19 in solid organ transplant recipients: Dynamics of disease progression and inflammatory markers in ICU and non-ICU admitted patients.
    Roberts MB; Izzy S; Tahir Z; Al Jarrah A; Fishman JA; El Khoury J
    Transpl Infect Dis; 2020 Oct; 22(5):e13407. PubMed ID: 32654303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-transplant diabetes mellitus. The role of immunosuppression.
    Jindal RM; Sidner RA; Milgrom ML
    Drug Saf; 1997 Apr; 16(4):242-57. PubMed ID: 9113492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Administration of Antithymocyte Globulin (Rabbit) to Treat a Severe, Mixed Rejection Episode in a Pregnant Renal Transplant Recipient.
    Kutzler HL; Ye X; Rochon C; Martin ST
    Pharmacotherapy; 2016 Apr; 36(4):e18-22. PubMed ID: 26892892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction immunosuppression in kidney transplant recipients with HIV: To deplete or not to deplete?
    Agrawal A; Stosor V
    Transpl Infect Dis; 2024 Aug; 26(4):e14299. PubMed ID: 38953433
    [No Abstract]   [Full Text] [Related]  

  • 25. Antibody induction versus corticosteroid induction for liver transplant recipients.
    Penninga L; Wettergren A; Wilson CH; Chan AW; Steinbrüchel DA; Gluud C
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD010252. PubMed ID: 24880007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Immunosuppression in Solid Organ Transplantation.
    Konda P; Golamari R; Eisen HJ
    Handb Exp Pharmacol; 2022; 272():267-285. PubMed ID: 35318509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes.
    Shivaswamy V; Boerner B; Larsen J
    Endocr Rev; 2016 Feb; 37(1):37-61. PubMed ID: 26650437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction Versus Maintenance Immunosuppression After Intestinal Transplant: Determining Which Treatment Most Impacts Long-Term Patient And Graft Survival.
    Gentilini MV; Perez-Illidge L; Pedraza N; Nemirovsky SI; Fernandez MF; Ramisch D; Solar H; Rumbo M; Rumbo C; Gondolesi GE
    Exp Clin Transplant; 2022 Dec; 20(12):1105-1113. PubMed ID: 36718010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nutritional and metabolic issues in solid organ transplantation: targets for future research.
    Ward HJ
    J Ren Nutr; 2009 Jan; 19(1):111-22. PubMed ID: 19121784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugs.
    Parlakpinar H; Gunata M
    Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):651-665. PubMed ID: 34415233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Care for the organ transplant recipient on the intensive care unit.
    van den Hoogen MWF; Seghers L; Manintveld OC; Roest S; Bekkers JA; den Hoed CM; Minnee RC; de Geus HRH; van Thiel RJ; Hesselink DA
    J Crit Care; 2021 Aug; 64():37-44. PubMed ID: 33784577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunosuppressant-induced cutaneous drug reactions in solid organ transplant recipients.
    Miotto IZ; Souza BCE; Tyring SK; de Oliveira WRP
    Transpl Immunol; 2021 Feb; 64():101355. PubMed ID: 33264680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunosuppressive therapy post-transplantation in children: what the clinician needs to know.
    Tönshoff B
    Expert Rev Clin Immunol; 2020 Feb; 16(2):139-154. PubMed ID: 31952458
    [No Abstract]   [Full Text] [Related]  

  • 36. [Cytomegalovirus infection after solid-organ transplantation, its risk factors, direct and indirect effects and prevention strategies].
    Varga M; Remport A; Czebe K; Péter A; Toronyi E; Sárváry E; Fehérvári I; Sulyok B; Járay J
    Orv Hetil; 2008 Mar; 149(12):551-8. PubMed ID: 18343771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunosuppression management in renal transplant recipients with normal-immunological risk: 10-year results from the Swiss Transplant Cohort Study.
    Krisl A; Stampf S; Hauri D; Binet I; Mueller T; Sidler D; Hadaya K; Golshayan D; Pascual M; Koller M; Dickenmann M; The Swiss Transplant Cohort Study Stcs
    Swiss Med Wkly; 2020 Nov; 150():w20354. PubMed ID: 33277913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infections following rejection therapies in kidney and liver transplant recipients.
    Gupta S; Gea-Banacloche J; Me HM; Chascsa DMH; Heilman RL; Budhiraja P; Yaman RN; Vikram HR; Zhang N; Joseph AM; Kodali L
    Transpl Infect Dis; 2022 Dec; 24(6):e13981. PubMed ID: 36300873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients.
    Penninga L; Wettergren A; Wilson CH; Chan AW; Steinbrüchel DA; Gluud C
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD010253. PubMed ID: 24901467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenomics and beyond! Customized pharmacotherapy for solid organ transplant recipients.
    Lemke A; Wright J; May H
    Pharmacotherapy; 2023 Jul; 43(7):596-608. PubMed ID: 36999337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.